An automated approach to solving Pharma's cardiac toxicity conundrum

Drug Discovery World

Volumn 14, Issue 2, 2013, Pages 60-66

  Van De Waart, Beppy ^a   Westerink, Walter ^a   Costas, Nuria Piñeiro ^a  

^a WIL Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ALFUZOSIN; ASTEMIZOLE; CAFFEINE; CHLOROQUINE; CISAPRIDE; CITALOPRAM; CLEMASTINE; CLOMIFENE; DOFETILIDE; FLUOXETINE; MOXIFLOXACIN; POTASSIUM CHANNEL HERG; QUINIDINE; RANOLAZINE; TERFENADINE; VERAPAMIL;

AUTOMATION; CARDIOTOXICITY; DRUG COST; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; FALSE POSITIVE RESULT; HUMAN; IC 50; IN VITRO STUDY; PATCH CLAMP; QT PROLONGATION; REVIEW; RISK ASSESSMENT;

EID: 84877075182     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Kola, I, Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3(8):711-715. (Pubitemid 39173511)
2. Pammolli, F, Magazzini, L, Riccaboni, M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 2011; 10(6):428-438.
3. Thomas, CE, Will, Y. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery. Expert Opin Drug Discov 2012; 7(2):109-122.
4. Schoonen, WG, Westerink, WM, Horbach, GJ. High-throughput screening for analysis of in vitro toxicity. EXS 2009; 99:401-452.
5. Moller, C, Witchel, H. Automated electrophysiology makes the pace for cardiac ion channel safety screening. Front Pharmacol 2011; 2:73.
6. Laverty, H, Benson, C, Cartwright, E, Cross, M, Garland, C, Hammond, T et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol 2011; 163(4):675-693.
7. Chiang, C. Drug-induced long QT syndrome. J Med Biol Eng 2006; 26(3): 107-113. (Pubitemid 44569287)
8. Stummann, TC, Beilmann, M, Duker, G, Dumotier, B, Fredriksson, JM, Jones, RL et al. Report and recommendations of the workshop of the European Centre for the Validation of Alternative Methods for Drug-Induced Cardiotoxicity. Cardiovasc Toxicol 2009; 9(3): 107-125.
9. Polonchuk, L. Toward a New Gold Standard for Early Safety: Automated Temperature- Controlled hERG Test on the PatchLiner. Front Pharmacol 2012; 3:3.
10. Scheel, O, Himmel, H, Rascher-Eggstein, G, Knott, T. Introduction of a modular automated voltage-clamp platform and its correlation with manual human Ether-a- go-go related gene voltage-clamp data. Assay Drug Dev Technol 2011; 9(6):600-607.
11. Stoelzle, S, Obergrussberger, A, Bruggemann, A, Haarmann, C, George, M, Kettenhofen, R et al. State-of-the-Art Automated Patch Clamp Devices: Heat Activation, Action Potentials and High Throughput in Ion Channel Screening. Front Pharmacol 2011; 2:76.
12. Yang, N. Cardiac drug safety and hERG channel. T Bio/Phar Ind 2012; 1:30-35.
13. Zhang, S, Zhou, Z, Gong, Q, Makielski, JC, January, CT Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 1999; 84(9):989-998. (Pubitemid 29227678)
14. Yuill, KH, Borg, JJ, Ridley, JM, Milnes, JT, Witchel, HJ, Paul, AA et al. Potent inhibition of human cardiac potassium (HERG) channels by the anti-estrogen agent clomiphene-without QT interval prolongation. Biochem Biophys Res Commun 2004; 318(2):556-561. (Pubitemid 38553815)
15. Ridley, JM, Milnes, JT, Hancox, JC, Witchel, HJ. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel. J Mol Cell Cardiol 2006; 40(1):107-118. (Pubitemid 43012122)
16. Pacher, P, Magyar, J, Szigligeti, P, Banyasz, T, Pankucsi, C, Korom, Z et al. Electrophysiological effects of fluoxetine in mammalian cardiac tissues. Naunyn Schmiedebergs Arch Pharmacol 2000; 361(1):67-73. (Pubitemid 30064656)
17. Witchel, HJ, Pabbathi, VK, Hofmann, G, Paul, AA, Hancox, JC. Inhibitory actions of the selective serotonin re-uptake inhibitor Citalopram on HERG and ventricular L-type calcium currents. FEBS Lett 2002; 512(1-3):59-66. (Pubitemid 34164451)
18. Lu, HR, Vlaminckx, E, Van de Water, A, Rohrbacher, J, Hermans, A, Gallacher, DJ. Invitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur J Pharmacol 2007; 577(1-3):222-232.
19. Antzelevitch, C, Belardinelli, L, Zygmunt, AC, Burashnikov, A, Di Diego, JM, Fish, JM et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110(8):904-910. (Pubitemid 39136212)
20. Lacerda, AE, Kuryshev, YA, Chen, Y, Renganathan, M, Eng, H, Danthi, SJ et al. Alfuzosin delays cardiac repolarization by a novel mechanism. J Pharmacol Exp Ther 2008; 324(2):427-433. (Pubitemid 351185830)
21. Rodriguez-Menchaca, AA, Navarro-Polanco, RA, Ferrer-Villada, T, Rupp, J, Sachse, FB, Tristani-Firouzi, M et al. The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel. Proc Natl Acad Sci U SA 2008; 105(4): 1364-1368. (Pubitemid 351397059)
22. Gintant, G. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther 2011; 129(2):109-119.